Drug intelligence / Profile preview

mitoxantrone hydrochloride liposome + dexamethasone + daratumumab

Development stage: Unknown
Lead developer: CSPC Zhongnuo Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of mitoxantrone hydrochloride liposome injection (Lipo-MIT), dexamethasone, and daratumumab. This regimen is being investigated for the treatment of relapsed/refractory multiple myeloma. Mitoxantrone hydrochloride liposome is a topoisomerase II inhibitor with antineoplastic properties, dexamethasone is a corticosteroid with anti-inflammatory and immunosuppressive effects, and daratumumab is a monoclonal antibody targeting CD38 on multiple myeloma cells.

Other names: Lipo-MIT + daratumumab + dexamethasoneMitoxantrone hydrochloride liposome injection combined with daratumumab and dexamethasone

Targets

TOP2A (DNA topoisomerase II)CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on mitoxantrone hydrochloride liposome + dexamethasone + daratumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitoxantrone hydrochloride liposome + dexamethasone + daratumumab.

Explore the full profile